These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10090433)

  • 1. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
    Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
    Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
    van Mourik ID; Thomson M; Kelly DA
    Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients.
    Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A
    Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of neoral in stable renal transplant recipients with long-term diabetes mellitus.
    Deel C; Nori U; Pescovitz MD; Govani MV
    Transplant Proc; 2007; 39(1):109-14. PubMed ID: 17275485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune.
    Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A
    Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
    Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
    Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study.
    Masri MA; Haberal M; Rizvi A; Stephan A; Bilgin N; Naqvi A; Barbari A; Kamel G; Zafar N; Emiroğlu R; Colak T; Manzoor K; Matha V; Kamarad V; Rizk S; Itany AR; Shehedeh I
    Transplant Proc; 2004; 36(1):80-3. PubMed ID: 15013306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions.
    Knoop C; Vervier I; Thiry P; De Backer M; Kovarik JM; Rousseau A; Marquet P; Estenne M
    Transplantation; 2003 Aug; 76(4):683-8. PubMed ID: 12973109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation.
    Kesten S; Scavuzzo M; Chaparro C; Szalai JP
    Pharmacotherapy; 1998; 18(4):847-50. PubMed ID: 9692659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
    Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
    J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.